Bioxytran (BIXT) 10-K 18 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 13, 2020	Jun. 30, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	BIOXYTRAN, INC
Entity Central Index Key	0001445815
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		88,025,673
Entity Public Float			$ 8,931,347
Entity File Number	001-35027
Entity Incorporation State Country Code	NV

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash	$ 169,628	$ 36,411
Other Receivable	50,000
Total current assets	219,628	36,411
Total assets	219,628	36,411
Current liabilities:
Accounts payable and accrued expenses	71,932	23,447
Accounts payable related party	96,000	10,900
Convertible notes payable, net of premium and discount	850,983	227,378
Total current liabilities	1,018,915	261,725
Total liabilities	1,018,915	261,725
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 50,000,000 shares authorized, nil issued and outstanding
Common stock, $0.001 par value; 300,000,000 shares authorized; 86,475,673 issued and outstanding as of December 31, 2019, and 85,103,673 issued and outstanding as of December 31, 2018	86,476	85,104
Additional paid in capital	1,355,542	72,412
Accumulated deficit	(2,241,305)	(382,830)
Total stockholders' equity (deficit)	(799,287)	(225,314)
Total liabilities and stockholders' equity (deficit)	$ 219,628	$ 36,411

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	86,475,673	85,103,673
Common stock, shares outstanding	86,475,673	85,103,673

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating expenses:
General and administrative	$ 507,273	$ 215,110
Compensation expense	1,124,194
Total operating expenses	1,631,467	215,110
Loss from operations	(1,631,467)	(215,110)
Other (expense):
Interest expense	(41,846)	(3,722)
Debt discount amortization	(185,163)	(77,585)
Total other (expenses) income	(227,009)	(81,307)
Net loss before provision for income taxes	(1,858,476)	(296,417)
Provision for income taxes
NET LOSS	$ (1,858,476)	$ (296,417)
Loss per common share, basic and diluted	$ (0.02)	$ 0
Weighted average number of common shares outstanding, basic and diluted	85,598,733	85,103,673

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($)	Common Stock	Preferred Stock	Additional Paid in Capital Common	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 85,104			$ (86,413)	$ (1,309)
Balance, shares at Dec. 31, 2017	85,103,673
Issuance of warrants			72,412		72,412
Net loss				(296,417)	(296,417)
Balance at Dec. 31, 2018	$ 85,104		72,412	(382,830)	(225,314)
Balance, shares at Dec. 31, 2018	85,103,673
Issuance of warrants			129,929		129,929
Options issued - 2010 Plan			257,143		257,143
Shares issued - 2010 Plan	$ 1,127		863,425		864,552
Shares issued - 2010 Plan, shares	1,127,000
Debt premium			(426,296)		(426,296)
Debt premium accretion			402,175		402,175
Shares issued for conversion of accrued interest	$ 225		36,775		37,000
Shares issued for conversion of accrued interest, shares	225,000
Shares issued for cash	$ 20		19,980		20,000
Shares issued for cash, shares	20,000
Net loss				(1,858,476)	(1,858,476)
Balance at Dec. 31, 2019	$ 86,476		$ 1,355,543	$ (2,241,304)	$ (799,287)
Balance, shares at Dec. 31, 2019	86,475,673

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,858,476)	$ (296,417)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount, incl. issuance of warrants	185,163	77,585
Stock-based compensation expense	1,121,694
Changes in operating assets and liabilities:
Other receivable	(50,000)
Accounts payable and accrued expenses	85,486	23,447
Accounts payable related party	85,100	9,481
Net cash provided by (used) in operating activities	(431,033)	(185,904)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	20,000
Proceeds from issuance of convertible notes payable	794,250	222,205
Re-payment of convertible note payable	(250,000)
Net cash provided by financing activities	564,250	222,205
Net increase (decrease) in cash	133,217	36,301
Cash, beginning of period	36,411	110
Cash, end of period	169,628	36,411
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	1,612
Income taxes paid	794,250
NON-CASH INVESTING & FINANCING ACTIVITIES
Issuance of Warrants	129,929	72,412
Debt discount on convertible note	60,038	22,622
Debt premium on convertible note	426,296
Accretion of debt premium to additional paid-in capital	(402,175)
Common shares issued for the conversion of accrued interest and principal	$ 37,000

Background and Organization

Background and Organization	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND AND ORGANIZATION	NOTE 1 – BACKGROUND AND ORGANIZATION Business Operations Bioxytran, Inc. (the "Company") is an early-stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues, in a safe and efficient manner. If it is not addressed, lack of oxygen to tissues, or hypoxia, results in necrosis, which is the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications to include treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The Company's initial focus is the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The Company's approach potentially will result in the creation of safe drug alternatives to existing therapies for effectively addressing hypoxic conditions in humans. Our drug development efforts are guided by specialists in co-polymer chemistry and other disciplines, and we intend to supplement our efforts with input from a scientific and medical advisory board whose members are leading physicians. Organization Bioxytan, Inc. was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 authorized common shares with a par value of $0.0001, and 5,000,000 preferred shares with a par value of $0.0001. On September 21, 2018, the Company went under a reorganization in form of a reverse merger and is currently registered as a Nevada corporation with a taxing structure for U.S. federal and state income tax as a C-Corporation with 300,000,000 authorized common shares with a par value of $0.001, and 50,000,000 preferred shares with a par value of $0.001 Basis of Presentation The summary of significant accounting policies presented below is designed to assist in understanding the Company's consolidated financial statements. Such financial statements and accompanying notes are the representations of the Company's management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") in all material respects and have been consistently applied in preparing the accompanying consolidated financial statements. The Company has not earned any revenue from operations since inception. The Company chose December 31 st Principles of Consolidation The accompanying consolidated financial statements include the accounts of Bioxytran, Inc. a Nevada Corporation and its wholly owned subsidiary, Bioxytran, Inc. of Delaware (collectively, the "Company"). All intercompany accounts have been eliminated upon consolidation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows. Cash For purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company's stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share ("ASC 260-10"). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the "treasury stock" and/or "if converted" methods as applicable. At December 31, 2019, we would, based on current market price of $0.285/share, be obligated to issue approximately 5,628,000 shares of common stock upon conversion of the currently outstanding Convertible Notes and 2,140,473 shares upon exercise of the warrants. For the Notes, the shares total is based on $901,274 of currently outstanding principal and unpaid interest. At December 31, 2018, we would, based on current market price of $0.51/share, be obligated to issue approximately 2,114,000 shares of common stock upon conversion of the outstanding Convertible Note and 208,333 shares upon exercise of the warrants. For the Notes, the shares total was based on $253,722 of currently outstanding principal and unpaid interest The conversion is priced to equal to the lesser of (i) the lowest trading price for the twenty-day period prior to the date of the Note or (ii) 65% of the lowest trading price during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Convertible Notes are limited to converting no more than 4.99% of our issued an outstanding common stock. Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award on the grant date Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2019, there were 341,000 outstanding stock options with a fair market value of $257,143 at the time of award and 1,127,000 shares issued with a fair market value of $864,551 at the time of award. At December 31, 2018, there were no outstanding stock options, nor any shares awarded. Income Taxes The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or be settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion of the gross deferred tax asset will not be realized. The Company records interest and penalties related to income taxes as a component of provision for income taxes. The Company did not recognize any interest and penalty expense for the years ended December 31, 2019 and 2018. On December 22, 2017, the Tax Cuts and Jobs Act (TCJA) was signed into law by the President of the United States. TCJA is a tax reform act that among other things, reduced corporate tax rates to 21 percent effective January 1, 2018. FASB ASC 740, Income Taxes, requires deferred tax assets and liabilities to be adjusted for the effect of a change in tax laws or rates in the year of enactment, which is the year in which the change was signed into law. Accordingly, the Company adjusted its deferred tax assets and liabilities at December 31, 2017, using the new corporate tax rate of 21 percent. See Note 8. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. During the year ended December 31, 2019 and December 31, 2018 the Company did not incur significant research and development expenses. Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10") requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures ("ASC 820-10") and Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10"), which permits entities to choose to measure many financial instruments and certain other items at fair value. Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

Going Concern and Management's

Going Concern and Management's Liquidity Plans	12 Months Ended
	Dec. 31, 2019
Going Concern and Management's Liquidity Plans [Abstract]
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	NOTE 3 – GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS As of December 31, 2019, the Company had cash of $169,628 and a negative working capital of $799,287. As of December 31, 2019, the Company has not yet generated any revenues, and has incurred cumulative net losses of $2,241,305. These conditions raise substantial doubt about the Company's ability to continue as a going concern. During the year ended December 31, 2019, the Company has raised a net of $794,250, while we have paid back $636,900 from issuance of debt in form of convertible notes, and $20,000 in cash proceeds from the issuance of common stock. During the same period in 2018 the company had raised a net of $222,205 from issuance of debt in form of convertible notes. The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of March 2020 and is pursuing alternative opportunities to funding. The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. Accordingly, the accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

Accounts Payables and Accrued E

Accounts Payables and Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2019
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 4 – ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES On December 31, 2019, there was $96,000 Accrued Expenses in Accounts Payables to related parties in form of payroll and advanced expenses. On December 31, 2018 there was $10,900 Accrued Expenses in Accounts Payables to related parties. The following table represents the major components of accounts payables and accrued expenses and other current liabilities at December 31, 2019 and December 31, 2018: December 31, December 31, Accounts Payables related party (1) $ 96,000 $ 10,900 Professional fees 42,963 19,175 Interest 14,374 3,722 Payroll Taxes 7,344 - Other Accounts Payables 7,251 550 Convertible Note Payables 850,983 227,378 Total $ 1,018,915 $ 261,725 (1) 48,000 to each the CFO and the CEO for 8 months of salary for the period May through December 2019, 10,900 to the CFO for 1 month of salary and prepaid expenses during December 2018

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 5 – CONVERTIBLE NOTES PAYABLE As long as the following convertible notes remain outstanding, the Company cannot amend its charter in any matter that materially effects rights of noteholders, repay or repurchase more than de minimis number of shares of common stock other than conversion or warrant shares, repay or repurchase all or any portion of any indebtedness, or pay cash dividends. Auctus Note #1 On October 24, 2018 (the "Date of Issuance") the Company issued a convertible promissory note (the "Auctus Note #1") with a face value of $250,000, maturing on October 23, 2019, and a stated interest of 8% to a third-party investor. The Auctus Note #1 is convertible into common stock of the Company, par value $.001 per share (the "Common Stock") at any time after the earlier of: (i) 180 days from the date of the Auctus Note #1, or (ii) upon effective date of a registration statement. The conversion price of the Auctus Note #1 is equal to the lesser of: (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #1 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Auctus Note #1 was funded on October 29, 2018, when the Company received proceeds of $222,205, after disbursements for the lender's transaction costs, fees and expenses which in aggregate resulted in a total discount of $27,795 to be amortized to interest expense over the life of the Auctus Note #1. Additionally, the variable conversion rate component requires that the Auctus Note #1 be valued at its stock redemption value (i.e., "if-converted" value) pursuant to ASC 480, Distinguishing Liabilities from Equity Along with the Auctus Note #1, on the Date of Issuance the Company issued 208,333 Common Stock Purchase Warrants (the "Warrants"), exercisable immediately at a fixed exercise price of $0.60 with an expiration date of October 23, 2023. The Company has determined that the Warrants are exempt from derivative accounting and were valued at $101,937 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.49 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 251% and (5) risk free interest rate of 2.51%. The note proceeds of $250,000 were then allocated between the fair value of the Auctus Note #1 ($250,000) and the Warrants ($101,937), resulting in a debt discount of $72,412. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance. The Auctus Note #1 was payed-off at Maturity on 10/24/2019. Auctus Note #2 On February 25, 2019, the Company entered into a $250,000 Senior Secured Promissory Note ("the Auctus Note #2"), dated February 25, 2019 at an interest rate of 8% per annum, maturing on February 24, 2020 (the "Maturity Date"). Issuance fees totaling $27,750 were recorded as a debt discount, resulting in net proceeds of $222,250. The Auctus Note #2 is convertible into common stock of the Company, par value $.001 per share (the "Common Stock") at any time after the earlier of: (i) 180 days from the date of the Auctus Note #2 or (ii) upon effective date of a new registration statement. The conversion price of the Auctus Note #2 is equal to the lesser of: (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #2 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Company may prepay the Auctus Note #2 at any time at a rate of 120% of outstanding principal and interest during the first 90 days it is outstanding and 130% of outstanding principal and interest for the next 90 days thereafter. Thereafter the prepayment amount increases 5% for each thirty-day period until 270 days from the issue date at which time it is fixed at 150% of the outstanding principal and interest on the Auctus Note #2. Additionally, the variable conversion rate component requires that the Auctus Note #2 be valued at its stock redemption value (i.e., "if-converted" value) pursuant to ASC 480, Distinguishing Liabilities from Equity, with the excess over the undiscounted face value being deemed a premium to be added to the principal balance and accreted to additional paid-in capital over the life of the Auctus Note #2. As such, the Company recorded a premium of $82,500 as a reduction to additional paid-in capital based on a discounted "if-converted" rate of $0.20 per share (lowest trading price during the 20 days preceding the note's issuance), which computed to 1,250,000 shares of 'if-converted' common stock with a redemption value of $332,500 due to $0.266 per share fair market value of the Company's stock on the Auctus Note #2's date of issuance. Debt discount amortization is recorded as interest expense, while debt premium accretion is recorded as an increase to additional paid-in capital. For the year ended at December 31, 2019, the Company amortized $16,271 debt discount to operations as interest expense, and accreted $16,949 of premium to additional paid-in capital. Along with the the Auctus Note #2, on the Date of Issuance the Company issued 208,333 Common Stock Purchase Warrants (the "Warrants"), exercisable immediately at a fixed exercise price of $0.60 with an expiration date of February 24, 2024. The Company has determined that the Warrants are exempt from derivative accounting and were valued at $55,417 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.27 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 358% and (5) risk free interest rate of 2.48%. The Auctus Note #2 proceeds of $250,000 were then allocated between the fair value of the Auctus Note #2 ($250,000) and the Warrants ($55,417), resulting in a debt discount of $45,361. As the warrants are exercisable immediately, this debt discount was amortized in its entirety to issuance of warrants (other expenses) on the Date of Issuance. In the period October 23, 2019 through December 30, 2019, the Company entered into five separate Secured Promissory Note Agreements ("SPA") with a face value of $636,900, and received net proceeds of $572,000. The Notes are convertible into common stock of the Company, par value $.001 per share (the "Common Stock") at any time after the earlier of: (i) 180 days from the date of the Note or (ii) upon effective date of a registration statement. The conversion price of the Notes is equal to 65% of the lowest trading price at close during the twenty days prior to a conversion notice. The debt discount of $64,900 is amortized over the duration of the loans. The Debentures permit the Company to pre-pay its obligations at a premium prior to maturity. Further, the Company issued five-year warrants with cashless exercise provisions to purchase a total of 200,000 shares of Common Stock of the Company at an exercise price of $2.00 per share with cashless exercise provisions to four of the Lenders. The Company has determined that the Warrants are exempt from derivative accounting. The note proceeds of $636,900 were then allocated between the fair value of the Notes ($636,900) and the Warrants ($103,200), resulting in a debt discount of resulting in a fully amortized debt discount of $84,568. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance. A summary of the outstanding notes at December 31, 2019, are as follows: Debtor Date of Maturity Principal Net Interest Warrants Issued Term Exercise Amortization Debt Auctus Note #2 02/25/2019 02/25/2020 $ 250,000 $ 222,250 8 % 208,333 5 $ 0.60 $ 45,361 $ 27,795 GS Capital 10/30/2019 10/30/2020 125,000 109,500 4 % 50,000 5 2.00 23,867 15,500 Power Up 10/24/2019 10/23/2020 106,000 100,000 8 % - - - - 6,000 Peak One 10/23/2019 10/22/2022 120,000 103,000 0 % 50,000 5 2.00 21,606 17,000 Tangiers 10/23/2019 10/22/2020 106,300 100,000 8 % 50,000 5 2.00 21,116 6,300 FirstFire 11/20/2019 11/20/2020 125,000 109,500 4 % 50,000 5 2.00 17,979 15,500 Power Up 12/30/2019 12/30/2020 54,600 50,000 * 8 % - - - - 4,600 $ 886,900 $ 794,250 408,333 $ 129,929 $ 92,695 * Deposit in transit Convertible notes payable consists of the following at December 31, 2019 and December 31, 2018: December 31, December 31, Principal balance $ 886,900 $ 250,000 Unamortized debt discount (60,038 ) (22,622 ) Unamortized debt premium 24,121 - Outstanding, net of debt discount and premium $ 850,983 $ 227,378

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 6 – STOCKHOLDERS' EQUITY At a Board of Director's Meeting on July 30, 2018, the Company authorized a reverse split that resulted in a reduction of the number of outstanding and issued shares of both common and preferred stock so that after the split became effective on August 13, 2018, the shares of both common and preferred stock were reduced to 1 share for each 30 shares currently issued and outstanding. The effect on the Balance Sheet is a transfer of value from stock value at par to Additional Paid-in Capital. As a result of the one (1) for thirty (30) reverse stock split, the Company will continue to be authorized to issue 300,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock. The reverse split has been retroactively applied to all periods presented. Preferred stock As of December 31, 2019 and 2018, no preferred shares have been designated or issued. Common stock On May 30, 2019, 25,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #1 at $0.20 per share for a total of $5,000. On July 18, 2019, 25,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #1 at $0.20 per share for a total of $5,000. On August 20, 2019, 20,000 shares of common stock were sold and issued from the active S-1 at $1 per share for a total of $20,000. On August 22, 2019, 25,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #1 at $0.20 per share for a total of $5,000. On October 8, 2019, 50,000 shares of common stock were issued as a result of conversion of principal as well as accrued interest on the Auctus Note #1 at $0.20 per share for a total of $10,000. On November 8, 2019, 100,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #2 at $0.12 per share for a total of $12,000. Between November 2, 2018 and December 31, 2019, 1,127,000 shares were awarded with an average cost per share of $0.77, under the 2010 Stock Plan for a total value of $864,551. For details, see Shares Awarded and Issued under Note 5. As of December 31, 2019, the Company has 86,475,673 shares of common stock issued and outstanding. At December 31, 2018 there were 85,103,673 shares of common stock issued and outstanding. Common Stock Options/Warrants For the year ended December 31, 2019 the Company issued 408,333 Warrants as part of a convertible note agreements. The warrants total value allocated to debt discount was $129,929. For the year ended December 31, 2018 the Company issued 208,333 Warrants as part of a convertible note agreement. The warrants total value allocated to debt discount was $72,412. For details, see Convertible Note Payable under Note 3. The following table summarizes the Company's common stock warrant activity for the year ended December 31, 2019 and 2018: Weighted Weighted- Number of Warrants Exercise Expected Outstanding as of January 1, 2018 - $ - - Granted 208,333 0.60 5.0 Exercised - - - Forfeited/Cancelled - - - Outstanding as of December 31, 2018 208,333 $ 0.60 4.8 Granted 408,333 1.29 5.0 Exercised - - - Forfeited/Cancelled - - - Outstanding as of December 31, 2019 616,666 $ 1.06 4.2 Through December 31, 2019 there were 341,000 options were awarded under the 2010 Stock Option Plan. The options total fair value at the time of award was $257,143. There were no options awarded in 2018. The following table summarizes the Company's common stock warrant and options activity for the year ended at December 31, 2019 and the year ended December 31, 2018: Weighted Weighted- Number of Options Exercise Expected Outstanding as of January 1, 2018 - $ - - Granted - - - Exercised - - - Forfeited/Cancelled - - - Outstanding as of December 31, 2018 - $ - - Granted 341,000 0.96 3.0 Exercised - - - Forfeited/Cancelled - - - Outstanding as of December 31, 2019 341,000 $ 0.96 2.7

Stock Option Plan and Stock-Bas

Stock Option Plan and Stock-Based Compensation	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION	NOTE 7 – STOCK OPTION PLAN AND STOCK-BASED COMPENSATION During the year ended December 31, 2010, the Company adopted a stock option plan entitled "The 2010 Stock Plan" (2010 Plan) under which the Company may grant Options to Purchase Stock, Stock Awards or Stock Appreciation Rights up to 15% of common stock, automatically adjusted on January 1 each year. As of December 31, 2018, there were no outstanding awards under the 2010 Plan. As of December 31, 2019, there were 341,000 outstanding stock options with a fair market value of $257,143 and 1,127,000 shares issued with a fair market value of $864,551 at the time of award. At December 31, 2018, there were no outstanding stock options, nor any shares awarded. Under the terms of the stock plans, the Board of Directors shall specify the exercise price and vesting period of each stock option on the grant date. Vesting of the options is typically immediate and the options typically expire in five years. Stock Awards may be directly issued under the Plan (without any intervening options). Stock Awards may be issued which are fully and immediately vested upon issuance. Shares Awarded and Issued: On November 2, 2018, the Company granted 4,000 shares with a fair market value of $0.51 to four members of the Company Board as compensation for their contribution in the Company's Board of Directors, for a total of $2,040. The shares were issued in 2019. On November 6, 2018, the Company granted 1,000 shares with a fair market value of $0.52 to one member of the Audit Committee as compensation for his contribution in this Company Committee, for a total of $520. The shares were issued in 2019. On November 29, 2018, the Company granted 4,000 shares with a fair market value of $1.00 to four members of the Audit Committee as compensation for his contribution in this Company Committee, for a total of $4,000. The shares were issued in 2019. On March 7, 2019, the Company granted 3,000 shares with a fair market value of $0.27 to three members of the Audit Committee as compensation for their contribution in the Audit Committee, for a total of $810. On March 11, 2019 the Company granted 100,000 shares with a fair market value of $0.266, to a consultant as compensation for their work with the Company's IR, for a total of $26,600. On May 10, 2019 the Company granted 3,000 shares with a fair market value of $1.00 to three members of the Audit Committee as compensation for their contribution in the Audit Committee, for a total of $3,000. On May 17, 2019, the Company granted 4,000 shares with a fair market value of $1.49 to four members of the Company Board as compensation for their contribution in the Company's Board of Directors, for a total of $5,960. On June 11, 2019 the Company granted 250,000 shares with a fair market value of $1.39 to a Financial Advisory Board Member for his contribution in the Company's Advisory Board, for a total of $347,500. On July 15, 2019 the Company granted 100,000 shares with a fair market value of $0.75 to a Financial Advisory Board Member for his contribution in the Company's Advisory Board, for a total of $75,000. On July 16, 2019 the Company granted 100,000 shares with a fair market value of $1.00 to a Financial Advisory Board Member for his contribution in the Company's Advisory Board, for a total of $100,000. On August 9, 2019, the Company granted 2,000 shares with a fair market value of $0.80 to two members of the Audit Committee as compensation for their contribution in the Audit Committee, for a total of $1,600. On October 17, 2019 the Company granted 3,000 shares with a fair market value of $0.60 to four members of the Company Board as compensation for their contribution in the Company's Board of Directors, for a total of $1,800. On October 21, 2019 the Company granted 300,000 shares with a fair market value of $0.554 at the time of award, to a consultant as compensation for their work with the Company's IR, for a total of $166,283. On November 8, 2019 the Company granted 3,000 shares with a fair market value of $0.65 to four members of the Company Board as compensation for their contribution in the Company's Board of Directors, for a total of $1,950. On November 11, 2019 granted a subcontractor 250,000 shares with a fair market value of $0.51 at the time of award, as compensation for their work with the Company's IR, for a total of $127,500. Number of Shares Fair Value Weighted Shares Granted as of December 31, 2018 - $ - $ - Shares Granted 1,127,000 0.27 - 1.49 0.77 Shares Granted not Issued as of December 31, 2019 1,127,000 $ 0.27 - 1.49 $ 0.77 For the year ended December 31, 2019, the Company recorded stock-based compensation expense of $864,551 in connection with share-based payment awards. The Company did not record any recorded stock-based compensation expense during 2018. Stock options granted and vested: On May 1, 2019, the Company granted 45,000 three-year options at an exercise price of $1.21, to a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $44,820. On July 1, 2019 the Company granted 3,000 three-year options at an exercise price of $1.09 to a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $2,447. On August 1, 2019 the Company granted 45,000 three-year options at an exercise price of $1.10 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $39,731. On September 13, 2019 the Company granted 200,000 three-year options at an exercise price of $0.95 to two Financial Advisory Board Members for their contribution in the Company's Advisory Board. The options total fair value at the time of award was $141,060. On October 1, 2019 the Company granted 3,000 three-year options at an exercise price of $0.73 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $1,635. On November 1, 2019 the Company granted 45,000 three-year options at an exercise price of $0.61 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $27,450. The fair value of stock options granted and revaluation of non-employee consultant options for the year ended December 31, 2019 was calculated with the following assumptions: 2019 Risk-free interest rate 1.34 - 2.32 % Expected dividend yield 0 % Volatility factor (weekly) 122.25 % Expected life of option 3 years For the year ended December 31, 2019, the Company recorded compensation expense of $257,143 in connection with awarded stock options. The Company did not record any awarded option valuation as compensation expense during 2018. As at December 31, 2019, there was no unrecognized compensation expense related to non-vested stock option awards. The following table summarizes the Company's stock option activity during the year ended at December 31, 2019: Number of Shares Exercise Weighted Outstanding as of December 31, 2018 - $ - $ - Granted 341,000 0.61 - 1.21 0.96 Exercised - - - Options forfeited/cancelled - - - Outstanding as of December 31, 2019 341,000 $ 0.61 - 1.21 $ 0.96 The following table summarizes information about stock options that are vested or expected to vest at December 31, 2019: Options Outstanding Exercisable Options Exercise Number of Options Weighted Average Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic $ 0.61 45,000 $ 0.61 2.84 $ - 45,000 $ 0.61 2.84 $ - 0.73 3,000 0.73 2.73 - 3,000 0.73 2.73 - 0.95 200,000 0.95 2.70 - 200,000 0.95 2.70 - 1.09 3,000 1.09 2.50 - 3,000 1.09 2.50 - 1.10 45,000 1.10 2.58 - 45,000 1.10 2.58 - 1.21 45,000 1.21 2.33 - 45,000 1.21 2.33 - $ 0.61-1.21 341,000 $ 0.96 2.65 $ - 341,000 $ 0.96 2.65 $ - The following table sets forth the status of the Company's non-vested stock options as of December 31, 2019 and December 31, 2018: Number of Weighted- Non-vested as of December 31, 2018 - $ - Granted 341,000 0.77 Forfeited - - Vested 341,000 0.77 Non-vested as of December 31, 2019 - $ - The weighted-average remaining contractual life for options exercisable at December 31, 2019 is 2.65 years. The aggregate intrinsic value for fully vested, exercisable options was $0 at December 31, 2019. The aggregate intrinsic value of options exercised for the year ended at December 31, 2019 was $0 as no options were exercised. The actual tax benefit realized from stock option exercises for the year ended at December 31, 2018 was no options available for exercise. At December 31, 2019 the Company has 11,297,551 options or stock awards available for grant under the 2010 Plan.

Provision for Income Taxes

Provision for Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Provision for Income Taxes	NOTE 8 – PROVISION FOR INCOME TAXES Provision for Income Taxes During the year ended December 31, 2019 and December 31, 2018, no provision for income taxes was recorded as the Company generated net operating losses. The tax effects of temporary differences that give rise to deferred tax assets are presented below: 2019 2018 Deferred Tax Assets: Net operating loss carryforward $ 832,590 $ 226,660 Total deferred tax assets 174,840 47,590 Valuation allowance (174,840 ) (47,590 ) Deferred tax asset, net of valuation allowance $ - $ - A reconciliation of the statutory federal income tax rate to the Company's effective tax rate is as follows: Tax benefit at federal statutory rate (21.0 )% (21.0 )% The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company's history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized. At December 31, 2019, the Company had approximately $832,590 of federal net operating losses that may be available to offset future taxable income, At December 31, 2018, the Company had approximately $226,660 of federal net operating losses that may be available to offset future taxable income. $2,870 of the net operating loss carry forwards (NOL), if not utilized, will expire in 2037 for federal purposes, the remaining amount of NOL can be carried forward indefinitely. As of the fiscal year 2019, a deduction for issued warrants and stock options and restricted shares awarded from the 2010 Stock Plan for a total of $1,324,035 has not yet been made, for the fiscal year 2018 this total was $72,412. The market value less exercise price for these awards will be deducted if and when the warrants and stock options are exercised, while the restricted shares will be deducted at market value at the date they were awarded, once the restriction is removed. Pursuant to the Internal Revenue Code Section 382 ("Section 382"), certain ownership changes may subject the net operating loss carryforwards ("carryforwards") and research and development tax credit carryforwards to annual limitations which could reduce or defer the carryforwards. Section 382 imposes limitations on a corporation's ability to utilize carryforwards if it experiences an ownership change. An ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percentage points over a three-year period. In the event of an ownership change, utilization of the carryforwards would be subject to an annual limitation under Section 382 determined by multiplying the value of its stock at the time of the ownership change by the applicable long-term tax-exempt rate. Any unused annual limitation may be carried over to later years. The imposition of this limitation on its ability to use the carryforwards to offset future taxable income could cause the Company to pay U.S. federal income taxes earlier than if such limitation were not in effect and could cause such carryforwards to expire unused, reducing or eliminating the benefit of such carryforwards. The Company has not completed a Section 382 study to determine if there have been one or more ownership changes due to the costs associated with such a study. Until a study is completed and the extent of the limitations, if any, is able to be determined, no additional amounts have been written off or are being presented as an uncertain tax position. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cut and Jobs Act (the "Tax Act"). The Tax Act establishes new tax laws that affects 2018 and future years, including a reduction in the U.S. federal corporate income tax rate to 21%, effective January 1, 2018 The Company applies the provisions of ASC 740-10, Income Taxes. The Company has not recognized any liability for unrecognized tax benefits and does not believe there is any uncertainty with respect to its tax position. The Company's policy with respect to unrecognized tax benefits is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending income tax examinations. Earlier years may be examined to the extent that tax credit or net operating loss carryforwards are used in future periods. The Company's policy is to record interest and penalties related to income taxes as part of its income tax provision.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES Employment contracts The Company's executive officers have entered employment contracts and confidentiality, non-disclosure and assignment of invention agreements. The employment agreements do not provide for the payment of any compensation to our executive officers but provide for the payment of $100,000 in severance upon termination of employment without cause and make no provisions for any payment upon a change of control. Litigation In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Legal fees for such matters are expensed as incurred and we accrue for adverse outcomes as they become probable and estimable.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 – SUBSEQUENT EVENTS The Company has evaluated events from December 31, 2019 through the date the financial statements were issued. The events requiring disclosure for this period are as follows; Common stock On January 3, 2020, 100,000 shares of common stock were issued as a result of conversion of accrued interest and principal on the Auctus Note #2 for a total of $12,000. On February 18, 2020, 250,000 shares of common stock were issued as a result of conversion of accrued interest and principal on the Auctus Note #2 for a total of $21,632. On March 12, 2020, 750,000 of common stock were issued in exchange for 416,666 warrants in a cashless exercise, originating from Auctus Notes #1 and #2 for a total of $250,500. Shares Awarded and Issued under the 2010 Stock Plan: On January 1, 2020 the Company granted 250,000 shares with a fair market value of $0.285/share at the time of award, to a consultant for assistance with the Companies PR work, for a total of $71,250. On January 31, 2020 the Company granted two subcontractors a total of 200,000 shares with a fair market value of $0.14/share at the time of award, as compensation for their work with the Company's marketing efforts, for a total of $28,000. Options Awarded and Issued under the 2010 Stock Plan: On January 1, 2019 the Company granted 3,000 three-year options at an exercise price of $0.31 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $603. On February 1, 2020 the Company granted 45,000 three-year options at an exercise price of $0.15 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $4,401. Issuance of Convertible Notes Payables During the period January 10, 2020 through February 19, 2020, the Company entered into three separate 1-year Secured Promissory Note Agreements ("SPA") with a face value of $236,600, and received net proceeds of $209,500. The Notes are convertible into common stock of the Company, par value $.001 per share (the "Common Stock") at any time after the earlier of: (i) 180 days from the date of the Note or (ii) upon effective date of a registration statement. The conversion price of the Notes is equal to 65% of the lowest trading price at close during the twenty days prior to a conversion notice. The debt discount of $31,000 is amortized over the duration of the loans. The Debentures permit the Company to pre-pay its obligations at a premium prior to maturity. Further, the Company issued five-year warrants with cashless exercise provisions to purchase a total of 72,000 shares of Common Stock of the Company at an exercise price of $2.00 per share with cashless exercise provisions to the three Lenders. The Company has determined that the Warrants are exempt from derivative accounting. The note proceeds of $236,600 were then allocated between the fair value of the Notes ($236,600) and the Warrants ($18,547), resulting in a debt discount of resulting in a fully amortized debt discount of $16,002. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance. The proceeds from these Notes were used to pay off the Auctus Note #2, maturing on February 25, 2020, and for working capital. The Convertible Note transactions included in these subsequent events resulted in a Net Debt reduction of $13,400. Debtor Date of Maturity Principal Net Interest Warrants Issued Term Exercise Amortization Debt EMA Financial 01/10/2020 01/10/2021 $ 125,000 $ 109,500 4 % 50,000 5 $ 2.00 $ 5,948 $ 15,500 Crown Bridge 02/20/2020 02/20/2021 55,000 48,000 4 % 22,000 5 2.00 10,054 7,000 PowerUp 02/19/2020 02/19/2021 56,600 52,000 8 % - - - - 4,600 $ 236,600 $ 209,500 72,000 $ 16,002 $ 31,000 The management see no further subsequent events requiring disclosure.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Cash	Cash For purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company's stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Net Loss per Common Share, basic and diluted	Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share ("ASC 260-10"). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the "treasury stock" and/or "if converted" methods as applicable. At December 31, 2019, we would, based on current market price of $0.285/share, be obligated to issue approximately 5,628,000 shares of common stock upon conversion of the currently outstanding Convertible Notes and 2,140,473 shares upon exercise of the warrants. For the Notes, the shares total is based on $901,274 of currently outstanding principal and unpaid interest. At December 31, 2018, we would, based on current market price of $0.51/share, be obligated to issue approximately 2,114,000 shares of common stock upon conversion of the outstanding Convertible Note and 208,333 shares upon exercise of the warrants. For the Notes, the shares total was based on $253,722 of currently outstanding principal and unpaid interest The conversion is priced to equal to the lesser of (i) the lowest trading price for the twenty-day period prior to the date of the Note or (ii) 65% of the lowest trading price during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Convertible Notes are limited to converting no more than 4.99% of our issued an outstanding common stock.
Stock Based Compensation	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award on the grant date Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2019, there were 341,000 outstanding stock options with a fair market value of $257,143 at the time of award and 1,127,000 shares issued with a fair market value of $864,551 at the time of award. At December 31, 2018, there were no outstanding stock options, nor any shares awarded.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or be settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion of the gross deferred tax asset will not be realized. The Company records interest and penalties related to income taxes as a component of provision for income taxes. The Company did not recognize any interest and penalty expense for the years ended December 31, 2019 and 2018. On December 22, 2017, the Tax Cuts and Jobs Act (TCJA) was signed into law by the President of the United States. TCJA is a tax reform act that among other things, reduced corporate tax rates to 21 percent effective January 1, 2018. FASB ASC 740, Income Taxes, requires deferred tax assets and liabilities to be adjusted for the effect of a change in tax laws or rates in the year of enactment, which is the year in which the change was signed into law. Accordingly, the Company adjusted its deferred tax assets and liabilities at December 31, 2017, using the new corporate tax rate of 21 percent. See Note 8.
Research and Development	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. During the year ended December 31, 2019 and December 31, 2018 the Company did not incur significant research and development expenses.
Fair Value	Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10") requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures ("ASC 820-10") and Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10"), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

Accounts Payables and Accrued_2

Accounts Payables and Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of accounts payables and accrued expenses and other current liabilities	December 31, December 31, Accounts Payables related party (1) $ 96,000 $ 10,900 Professional fees 42,963 19,175 Interest 14,374 3,722 Payroll Taxes 7,344 - Other Accounts Payables 7,251 550 Convertible Note Payables 850,983 227,378 Total $ 1,018,915 $ 261,725 (1) 48,000 to each the CFO and the CEO for 8 months of salary for the period May through December 2019, 10,900 to the CFO for 1 month of salary and prepaid expenses during December 2018

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of outstanding notes	Debtor Date of Maturity Principal Net Interest Warrants Issued Term Exercise Amortization Debt Auctus Note #2 02/25/2019 02/25/2020 $ 250,000 $ 222,250 8 % 208,333 5 $ 0.60 $ 45,361 $ 27,795 GS Capital 10/30/2019 10/30/2020 125,000 109,500 4 % 50,000 5 2.00 23,867 15,500 Power Up 10/24/2019 10/23/2020 106,000 100,000 8 % - - - - 6,000 Peak One 10/23/2019 10/22/2022 120,000 103,000 0 % 50,000 5 2.00 21,606 17,000 Tangiers 10/23/2019 10/22/2020 106,300 100,000 8 % 50,000 5 2.00 21,116 6,300 FirstFire 11/20/2019 11/20/2020 125,000 109,500 4 % 50,000 5 2.00 17,979 15,500 Power Up 12/30/2019 12/30/2020 54,600 50,000 * 8 % - - - - 4,600 $ 886,900 $ 794,250 408,333 $ 129,929 $ 92,695 * Deposit in transit
Schedule of convertible notes payable	December 31, December 31, Principal balance $ 886,900 $ 250,000 Unamortized debt discount (60,038 ) (22,622 ) Unamortized debt premium 24,121 - Outstanding, net of debt discount and premium $ 850,983 $ 227,378

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of company's common stock warrants activity	Weighted Weighted- Number of Warrants Exercise Expected Outstanding as of January 1, 2018 - $ - - Granted 208,333 0.60 5.0 Exercised - - - Forfeited/Cancelled - - - Outstanding as of December 31, 2018 208,333 $ 0.60 4.8 Granted 408,333 1.29 5.0 Exercised - - - Forfeited/Cancelled - - - Outstanding as of December 31, 2019 616,666 $ 1.06 4.2 Weighted Weighted- Number of Options Exercise Expected Outstanding as of January 1, 2018 - $ - - Granted - - - Exercised - - - Forfeited/Cancelled - - - Outstanding as of December 31, 2018 - $ - - Granted 341,000 0.96 3.0 Exercised - - - Forfeited/Cancelled - - - Outstanding as of December 31, 2019 341,000 $ 0.96 2.7

Stock Option Plan and Stock-B_2

Stock Option Plan and Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Summary of fair value of stock awards granted	Number of Shares Fair Value Weighted Shares Granted as of December 31, 2018 - $ - $ - Shares Granted 1,127,000 0.27 - 1.49 0.77 Shares Granted not Issued as of December 31, 2019 1,127,000 $ 0.27 - 1.49 $ 0.77
Summary of stock options granted valuation assumptions	2019 Risk-free interest rate 1.34 - 2.32 % Expected dividend yield 0 % Volatility factor (weekly) 122.25 % Expected life of option 3 years
Summary of stock option activity	Number of Shares Exercise Weighted Outstanding as of December 31, 2018 - $ - $ - Granted 341,000 0.61 - 1.21 0.96 Exercised - - - Options forfeited/cancelled - - - Outstanding as of December 31, 2019 341,000 $ 0.61 - 1.21 $ 0.96
Summary of stock options vested or expected to vest	Options Outstanding Exercisable Options Exercise Number of Options Weighted Average Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic $ 0.61 45,000 $ 0.61 2.84 $ - 45,000 $ 0.61 2.84 $ - 0.73 3,000 0.73 2.73 - 3,000 0.73 2.73 - 0.95 200,000 0.95 2.70 - 200,000 0.95 2.70 - 1.09 3,000 1.09 2.50 - 3,000 1.09 2.50 - 1.10 45,000 1.10 2.58 - 45,000 1.10 2.58 - 1.21 45,000 1.21 2.33 - 45,000 1.21 2.33 - $ 0.61-1.21 341,000 $ 0.96 2.65 $ - 341,000 $ 0.96 2.65 $ -
Summary of non-vested stock options	Number of Weighted- Non-vested as of December 31, 2018 - $ - Granted 341,000 0.77 Forfeited - - Vested 341,000 0.77 Non-vested as of December 31, 2019 - $ -

Provision for Income Taxes (Tab

Provision for Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets	2019 2018 Deferred Tax Assets: Net operating loss carryforward $ 832,590 $ 226,660 Total deferred tax assets 174,840 47,590 Valuation allowance (174,840 ) (47,590 ) Deferred tax asset, net of valuation allowance $ - $ -
Schedule of effective tax rate	Tax benefit at federal statutory rate (21.0 )% (21.0 )%

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Schedule of convertible note payable	Debtor Date of Maturity Principal Net Interest Warrants Issued Term Exercise Amortization Debt EMA Financial 01/10/2020 01/10/2021 $ 125,000 $ 109,500 4 % 50,000 5 $ 2.00 $ 5,948 $ 15,500 Crown Bridge 02/20/2020 02/20/2021 55,000 48,000 4 % 22,000 5 2.00 10,054 7,000 PowerUp 02/19/2020 02/19/2021 56,600 52,000 8 % - - - - 4,600 $ 236,600 $ 209,500 72,000 $ 16,002 $ 31,000

Background and Organization (De

Background and Organization (Details) - $ / shares	Dec. 31, 2019	Dec. 31, 2018	Sep. 21, 2018	Oct. 05, 2017
Background and Organization (Textual)
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Delaware [Member]
Background and Organization (Textual)
Common stock, par value			$ 0.001	$ 0.0001
Common stock, shares authorized			300,000,000	95,000,000
Preferred stock, par value			$ 0.001	$ 0.0001
Preferred stock, shares authorized			50,000,000	5,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Summary of Significant Accounting Policies (Textual)
Stock-based compensation expense	$ 1,121,694
Market price per share	$ 0.285	$ 0.51
Conversion of common stock	5,628,000	2,114,000
Exercise warrants		208,333
Principle amount	$ 901,274	$ 253,722
Convertible notes, description	(i) the lowest trading price for the twenty-day period prior to the date of the Note or (ii) 65% of the lowest trading price during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Convertible Notes are limited to converting no more than 4.99% of our issued an outstanding common stock.
Percentage of deferred tax assets and liabilities			21.00%
Stock Option [Member]
Summary of Significant Accounting Policies (Textual)
Options outstanding	341,000
Fair market value of stock options	$ 257,143
Fair market value of shares issued	1,127,000
Un-issued shares liability	$ 864,551
Stock Option [Member] | Warrant [Member]
Summary of Significant Accounting Policies (Textual)
Warrants outstanding	2,140,473	208,333

Going Concern and Management'_2

Going Concern and Management's Liquidity Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Going Concern and Management's Liquidity Plans (Textual)
Cash	$ 169,628	$ 36,411	$ 110
Negative working capital	799,287
Cumulative net losses	2,241,305	382,830
Proceeds from issuance of debt	794,250	222,205
Cash proceeds issuance of common stock	20,000
Paid back issuance of convertible debt	$ 636,900

Accounts Payables and Accrued_3

Accounts Payables and Accrued Expenses and Other Current Liabilities (Details) - USD ($)		Dec. 31, 2019	Dec. 31, 2018
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
Accounts Payables related party	[1]	$ 96,000	$ 10,900
Professional fees		42,963	19,175
Interest		14,374	3,722
Payroll Taxes		7,344
Other Accounts Payables		7,251	550
Convertible Note Payables		850,983	227,378
Total		$ 1,018,915	$ 261,725
[1]	48,000 to each the CFO and the CEO for 8 months of salary for the period May through December 2019, 10,900 to the CFO for 1 month of salary and prepaid expenses during December 2018.

Accounts Payables and Accrued_4

Accounts Payables and Accrued Expenses and Other Current Liabilities (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounts Payables and Accrued Expenses and Other Current Liabilities (Textual)
Accrued expenses in accounts payables to related parties	$ 96,000	$ 10,900
CFO and CEO [Member]
Accounts Payables and Accrued Expenses and Other Current Liabilities (Textual)
Accrued salary expenses	$ 48,000
Duration of accrued salary paid	8 months
CFO [Member]
Accounts Payables and Accrued Expenses and Other Current Liabilities (Textual)
Accrued salary expenses		$ 10,900
Duration of accrued salary paid		1 month

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Principal Amount		$ 886,900
Net Received		$ 794,250
Warrants Issued		408,333
Amortization of Warrants		$ 129,929
Debt Discount		$ 185,163	$ 77,585
Auctus Note #2 [Member]
Debtor		Auctus Note #2
Date of Issuance		Feb. 25, 2019
Maturity Date		Feb. 25, 2020
Principal Amount		$ 250,000
Net Received		$ 222,250
Interest		8.00%
Warrants Issued		208,333
Term		5 years
Exercise Price		$ 0.60
Amortization of Warrants		$ 45,361
Debt Discount		$ 27,795
GS Capital [Member]
Debtor		GS Capital
Date of Issuance		Oct. 30, 2019
Maturity Date		Oct. 30, 2020
Principal Amount		$ 125,000
Net Received		$ 109,500
Interest		4.00%
Warrants Issued		50,000
Term		5 years
Exercise Price		$ 2
Amortization of Warrants		$ 23,867
Debt Discount		$ 15,500
PowerUp [Member]
Debtor		Power Up
Date of Issuance		Oct. 24, 2019
Maturity Date		Oct. 23, 2020
Principal Amount		$ 106,000
Net Received		$ 100,000
Interest		8.00%
Warrants Issued
Exercise Price
Amortization of Warrants
Debt Discount		$ 6,000
Peak One [Member]
Debtor		Peak One
Date of Issuance		Oct. 23, 2019
Maturity Date		Oct. 22, 2022
Principal Amount		$ 120,000
Net Received		$ 103,000
Interest		0.00%
Warrants Issued		50,000
Term		5 years
Exercise Price		$ 2
Amortization of Warrants		$ 21,606
Debt Discount		$ 17,000
Tangiers [Member]
Debtor		Tangiers
Date of Issuance		Oct. 23, 2019
Maturity Date		Oct. 22, 2020
Principal Amount		$ 106,300
Net Received		$ 100,000
Interest		8.00%
Warrants Issued		50,000
Term		5 years
Exercise Price		$ 2
Amortization of Warrants		$ 21,116
Debt Discount		$ 6,300
FirstFire [Member]
Debtor		FirstFire
Date of Issuance		Nov. 20, 2019
Maturity Date		Nov. 20, 2020
Principal Amount		$ 125,000
Net Received		$ 109,500
Interest		4.00%
Warrants Issued		50,000
Term		5 years
Exercise Price		$ 2
Amortization of Warrants		$ 17,979
Debt Discount		$ 15,500
Power Up1 [Member]
Debtor		Power Up
Date of Issuance		Dec. 30, 2019
Maturity Date		Dec. 30, 2020
Principal Amount		$ 54,600
Net Received	[1]	$ 50,000
Interest		8.00%
Warrants Issued
Exercise Price
Amortization of Warrants
Debt Discount		$ 4,600
[1]	Deposit in transit

Convertible Notes Payable (De_2

Convertible Notes Payable (Details 1) - Convertible notes payable [Member] - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Principal balance	$ 886,900	$ 250,000
Unamortized debt discount	(60,038)	(22,622)
Unamortized debt premium	24,121
Outstanding, net of debt discount and premium	$ 850,983	$ 227,378

Convertible Notes Payable (De_3

Convertible Notes Payable (Details Textual) - USD ($)	Nov. 08, 2019	Oct. 23, 2019	Oct. 08, 2019	May 30, 2019	Oct. 24, 2018	Aug. 22, 2019	Jul. 18, 2019	Feb. 25, 2019	Dec. 31, 2019	Dec. 31, 2018	Feb. 15, 2019
Convertible Notes Payable (Textual)
Common stock per share									$ 0.001	$ 0.001
Principal balance									$ 886,900
Interest expense									41,846	$ 3,722
Additional paid-in capital									1,355,542	$ 72,412
Convertible notes payable [Member]
Convertible Notes Payable (Textual)
Principal balance									236,600
Auctus Note #1 [Member]
Convertible Notes Payable (Textual)
Debt discount									$ 20,853
Common stock per share					$ 0.001
Expiration date					Oct. 23, 2019				Oct. 24, 2019
Convertible note, description					(i) 180 days from the date of the Auctus Note #1, or (ii) upon effective date of a registration statement. The conversion price of the Auctus Note #1 is equal to the lesser of: (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #1 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Auctus Note #1 was funded on October 29, 2018, when the Company received proceeds of $222,205, after disbursements for the lender's transaction costs, fees and expenses which in aggregate resulted in a total discount of $27,795 to be amortized to interest expense over the life of the Auctus Note #1.
Determined warrants derivative, description					The Company has determined that the Warrants are exempt from derivative accounting and were valued at $101,937 on the Date of Inception using the Black Scholes Options Pricing Model.  Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.49 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 251% and (5) risk free interest rate of 2.51%.  The note proceeds of $250,000 were then allocated between the fair value of the Auctus Note #1 ($250,000) and the Warrants ($101,937), resulting in a debt discount of $72,412.
Principal balance					$ 250,000
Stated interest					8.00%
Debt premium					$ 343,796
Common stock purchase warrants issued	100,000		50,000	25,000		25,000	25,000
Accreted premium to additional paid-in capital									$ 306,820
Auctus Note #1 [Member] | Convertible notes payable [Member]
Convertible Notes Payable (Textual)
Common stock per share					$ 0.001
Expiration date					Oct. 23, 2023
Convertible note, description					“if-converted” rate of $0.20 per share (lowest trading price during the 20 days preceding the note’s issuance), which computed to 1,211,828 shares of ‘if-converted’ common stock with a redemption value of $593,796 due to $0.49 per share fair market value of the Company’s stock on the Auctus Note #1’s date of issuance. Debt discount amortization is recorded as interest expense, while debt premium accretion is recorded as an increase to additional paid-in capital. For the year ended at December 31, 2019, the Company amortized $20,853 debt discount to operations as interest expense, and accreted $306,820 of premium to additional paid-in capital. For the year ended December 31, 2018, the Company amortized $5,173 debt discount to operations as interest expense.
Warrants exercise price					$ 0.60
Common stock purchase warrants issued					208,333
Auctus Note #2 [Member]
Convertible Notes Payable (Textual)
Common stock per share		$ .001						$ 0.60			$ 0.60
Expiration date								Feb. 24, 2024
Convertible note, description		The Company issued five-year warrants with cashless exercise provisions to purchase a total of 200,000 shares of Common Stock of the Company at an exercise price of $2.00 per share with cashless exercise provisions to four of the Lenders. The Company has determined that the Warrants are exempt from derivative accounting. The note proceeds of $636,900 were then allocated between the fair value of the Notes ($636,900) and the Warrants ($103,200), resulting in a debt discount of resulting in a fully amortized debt discount of $84,568. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance.						The Company has determined that the Warrants are exempt from derivative accounting and were valued at $55,417 on the Date of Inception using the Black Scholes Options Pricing Model.  Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.27 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 358% and (5) risk free interest rate of 2.48%.  The Auctus Note #2 proceeds of $250,000 were then allocated between the fair value of the Auctus Note #2 ($250,000) and the Warrants ($55,417), resulting in a debt discount of $45,361.
Common stock purchase warrants issued								208,333
Interest expense									16,271
Additional paid-in capital									$ 16,949
Auctus Note #2 [Member] | Secured Promissory Note [Member]
Convertible Notes Payable (Textual)
Convertible notes issued								$ 27,750
Common stock per share								$ 0.001
Expiration date								Feb. 24, 2020
Convertible note, description		(i) 180 days from the date of the Note or (ii) upon effective date of a registration statement. The conversion price of the Notes is equal to 65% of the lowest trading price at close during the twenty days prior to a conversion notice. The debt discount of $64,900 is amortized over the duration of the loans. The Debentures permit the Company to pre-pay its obligations at a premium prior to maturity.						(i) 180 days from the date of the Auctus Note #2 or (ii) upon effective date of a new registration statement. The conversion price of the Auctus Note #2 is equal to the lesser of: (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #2 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Company may prepay the Auctus Note #2 at any time at a rate of 120% of outstanding principal and interest during the first 90 days it is outstanding and 130% of outstanding principal and interest for the next 90 days thereafter. Thereafter the prepayment amount increases 5% for each thirty-day period until 270 days from the issue date at which time it is fixed at 150% of the outstanding principal and interest on the Auctus Note #2.
Principal balance		$ 636,900						$ 250,000
Stated interest								8.00%
Net proceeds		$ 572,000						$ 222,250
Additional conversion description								The Company recorded a premium of $82,500 as a reduction to additional paid-in capital based on a discounted "if-converted" rate of $0.20 per share (lowest trading price during the 20 days preceding the note's issuance), which computed to 1,250,000 shares of 'if-converted' common stock with a redemption value of $332,500 due to $0.266 per share fair market value of the Company's stock on the Auctus Note #2's date of issuance.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of Options [Member]
Number of shares, Outstanding, Beginning balance
Number of shares, granted	341,000
Number of shares, exercised
Number of shares, Forfeited/Cancelled
Number of shares, Outstanding, Ending balance	341,000
Weighted-Average Exercise Price, Outstanding, Beginning balance
Weighted-Average Exercise Price, granted	0.96
Weighted-Average Exercise Price, exercised
Weighted-Average Exercise Price, Forfeited/Cancelled
Weighted-Average Exercise Price, Outstanding, Ending balance	$ 0.96
Weighted-Average Remaining Expected Term, Beginning balance	0 years	0 years
Weighted-Average Remaining Expected Term, Options granted	3 years
Weighted-Average Remaining Expected Term, Ending balance	2 years 8 months 12 days	0 years
Number of Warrants [Member]
Number of shares, Outstanding, Beginning balance	208,333
Number of shares, granted	408,333	208,333
Number of shares, exercised
Number of shares, Forfeited/Cancelled
Number of shares, Outstanding, Ending balance	616,666	208,333
Weighted-Average Exercise Price, Outstanding, Beginning balance	$ 0.60
Weighted-Average Exercise Price, granted	1.29	0.60
Weighted-Average Exercise Price, exercised
Weighted-Average Exercise Price, Forfeited/Cancelled
Weighted-Average Exercise Price, Outstanding, Ending balance	$ 1.06	$ 0.60
Weighted-Average Remaining Expected Term, Beginning balance	4 years 9 months 18 days	0 years
Weighted-Average Remaining Expected Term, Options granted	5 years	5 years
Weighted-Average Remaining Expected Term, Ending balance	4 years 2 months 12 days	4 years 9 months 18 days

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Nov. 08, 2019	Oct. 08, 2019	Aug. 20, 2019	May 30, 2019	Aug. 22, 2019	Jul. 18, 2019	Nov. 02, 2018	Jul. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Stockholders' Equity (Textual)
Description of reverse stock split								The Company authorized a reverse split that resulted in a reduction of the number of outstanding and issued shares of both common and preferred stock so that after the split became effective on August 13, 2018, the shares of both common and preferred stock were reduced to 1 share for each 30 shares currently issued and outstanding. The effect on the Balance Sheet is a transfer of value from stock value at par to Additional Paid-in Capital. As a result of the one (1) for thirty (30) reverse stock split, the Company will continue to be authorized to issue 300,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock.
Preferred stock, shares issued
Common stock, shares issued									86,475,673	85,103,673
Common stock, shares outstanding									86,475,673	85,103,673
Warrants as part of a convertible note agreement									408,333
Warrant [Member]
Stockholders' Equity (Textual)
Share price									$ 2
Warrants as part of a convertible note agreement									72,000
2010 Stock Plan [Member]
Stockholders' Equity (Textual)
Conversion of accrued interest							$ 864,551		$ 864,551
Shares issued for conversion of accrued interest, shares							1,127,000		1,127,000
Share price							$ 0.77		$ 0.77
Options granted									341,000
Options total fair value at the time of award									$ 257,143
Equity Option [Member] | Warrant [Member]
Stockholders' Equity (Textual)
Warrants as part of a convertible note agreement									408,333	208,333
Debt discount									$ 129,929	$ 72,412
Auctus Note #1 [Member]
Stockholders' Equity (Textual)
Conversion of accrued interest	$ 12,000	$ 10,000		$ 5,000	$ 5,000	$ 5,000
Shares issued for conversion of accrued interest, shares	100,000	50,000		25,000	25,000	25,000
Share price	$ 0.12	$ 0.20		$ 0.20	$ 0.20	$ 0.20
Active S-1 [Member]
Stockholders' Equity (Textual)
Conversion of accrued interest			$ 20,000
Shares issued for conversion of accrued interest, shares			20,000
Share price			$ 1

Stock Option Plan and Stock-B_3

Stock Option Plan and Stock-Based Compensation (Details) - Stock Awards Plan [Member]	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Shares Granted as of December 31, 2018 | shares
Shares Granted | shares	1,127,000
Shares Granted not Issued as of September 30, 2019 | shares	1,127,000
Fair Value per Share, Shares Granted
Weighted Average Market Value per Share, Shares Granted as of December 31, 2018
Weighted Average Market Value per Share, Shares Granted	0.77
Weighted Average Market Value per Share, Shares Granted as of September 30, 2019	0.77
Minimum [Member]
Fair Value per Share, Shares Granted	0.27
Fair Value per Share, Shares Granted not Issued	0.27
Maximum [Member]
Fair Value per Share, Shares Granted	1.49
Fair Value per Share, Shares Granted not Issued	$ 1.49

Stock Option Plan and Stock-B_4

Stock Option Plan and Stock-Based Compensation (Details 1)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Risk-free interest rate, Minimum	1.34%
Risk-free interest rate, Maximum	2.32%
Expected dividend yield	0.00%
Volatility factor (weekly)	122.25%
Expected life of option	3 years

Stock Option Plan and Stock-B_5

Stock Option Plan and Stock-Based Compensation (Details 2) - Stock Option [Member]	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Number of shares, Outstanding, Beginning balance | shares
Granted | shares	341,000
Exercised | shares
Options forfeited/cancelled | shares
Number of shares, Outstanding, Ending balance | shares	341,000
Exercise Price per Share, Outstanding as of December 31, 2018
Exercise Price per Share, Exercised
Exercise Price per Share, Options forfeited/cancelled
Exercise Price per Share, Outstanding as of September 30, 2019
Weighted-Average Exercise Price, Outstanding, Beginning balance
Weighted Average Exercise Price per Share, Granted	0.96
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Options forfeited/cancelled
Weighted-Average Exercise Price, Outstanding, Ending balance	0.96
Minimum [Member]
Exercise Price per Share, Granted	0.61
Exercise Price per Share, Outstanding as of September 30, 2019	0.61
Maximum [Member]
Exercise Price per Share, Granted	1.21
Exercise Price per Share, Outstanding as of September 30, 2019	$ 1.21

Stock Option Plan and Stock-B_6

Stock Option Plan and Stock-Based Compensation (Details 3)	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Exercise Price, Lower Range Limit	$ 0.61
Exercise Price, Upper Range Limit	$ 1.21
Options Outstanding, Number of Options | shares	341,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.96
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 7 months 24 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	341,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.96
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 7 months 24 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 0.61 [Member]
Options Outstanding, Number of Options | shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.61
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 10 months 3 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.61
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 10 months 3 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 0.73 [Member]
Options Outstanding, Number of Options | shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.73
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 8 months 23 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.73
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 8 months 23 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 0.95 [Member]
Options Outstanding, Number of Options | shares	200,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.95
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 8 months 12 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	200,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.95
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 8 months 12 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 1.09 [Member]
Options Outstanding, Number of Options | shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.09
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 6 months
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.09
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 6 months
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 1.10 [Member]
Options Outstanding, Number of Options | shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.10
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 6 months 29 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.10
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 6 months 29 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 1.21 [Member]
Options Outstanding, Number of Options | shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.21
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 3 months 29 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.21
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 3 months 29 days
Exercisable Options, Aggregate Intrinsic Value | $

Stock Option Plan and Stock-B_7

Stock Option Plan and Stock-Based Compensation (Details 4) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Number of Options, Non-vested as of December 31, 2018 | shares
Number of Options, Non-vested Granted | shares	341,000
Number of Options, Non-vested Forfeited | shares
Number of Options, Vested | shares	341,000
Number of Options, Non-vested as of September 30, 2019 | shares
Weighted-Average Grant-Date Fair Value, Non-vested as of December 31, 2018 | $ / shares
Weighted-Average Grant-Date Fair Value, Granted | $ / shares	0.77
Weighted-Average Grant-Date Fair Value, Forfeited | $ / shares
Weighted-Average Grant-Date Fair Value, Vested | $ / shares	0.77
Weighted-Average Grant-Date Fair Value, Non-vested as of December 31, 2018 | $ / shares

Stock Option Plan and Stock-B_8

Stock Option Plan and Stock-Based Compensation (Details Textual)	Nov. 11, 2019USD ($)Persons$ / sharesshares	Nov. 08, 2019USD ($)Persons$ / sharesshares	Nov. 02, 2019USD ($)$ / sharesshares	Oct. 17, 2019USD ($)Persons$ / sharesshares	Oct. 01, 2019USD ($)$ / sharesshares	Sep. 13, 2019USD ($)$ / sharesshares	Aug. 09, 2019USD ($)Persons$ / sharesshares	Jul. 16, 2019USD ($)Persons$ / sharesshares	Jul. 15, 2019USD ($)Persons$ / sharesshares	Jun. 11, 2019USD ($)Persons$ / sharesshares	May 17, 2019USD ($)Persons$ / sharesshares	May 10, 2019USD ($)Persons$ / sharesshares	May 01, 2019USD ($)$ / sharesshares	Mar. 11, 2019USD ($)Persons$ / sharesshares	Mar. 07, 2019USD ($)Persons$ / sharesshares	Nov. 29, 2018USD ($)Persons$ / sharesshares	Nov. 06, 2018USD ($)Persons$ / sharesshares	Nov. 02, 2018USD ($)Persons$ / sharesshares	Oct. 21, 2019USD ($)Persons$ / sharesshares	Aug. 01, 2019USD ($)$ / sharesshares	Jul. 01, 2019USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018shares	Dec. 31, 2010
Stock Option Plan and Stock Based Compensation (Textual)
Aggregate intrinsic value of options exercised | $
Share-based Payment Arrangement, Option [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options outstanding number | shares																						341,000
Options granted | shares																						341,000
Grants in period, weighted average grant date fair value | $ / shares																						$ 0.77
Stock-based compensation expense | $																						$ 257,143
Stock options exercised | shares
Board of Members [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares											4,000							4,000
Grants in period, weighted average grant date fair value | $ / shares											$ 1.49							$ 0.51
Number of persons | Persons											4							4
Options granted, value | $											$ 5,960							$ 2,040
Members Audit Committee [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares	250,000	3,000		3,000			2,000					3,000			3,000	4,000	1,000		300,000
Grants in period, weighted average grant date fair value | $ / shares	$ 0.51	$ 0.65		$ 0.60			$ 0.80					$ 1			$ 0.27	$ 1	$ 0.52		$ 0.554
Number of persons | Persons	1	4		4			2					3			3	4	1		1
Options granted, value | $	$ 127,500	$ 1,950		$ 1,800			$ 1,600					$ 3,000			$ 810	$ 4,000	$ 520		$ 166,283
Consultant [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares														100,000
Grants in period, weighted average grant date fair value | $ / shares														$ 0.266
Number of persons | Persons														1
Options granted, value | $														$ 26,600
Financial Advisory Board [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares								100,000	100,000	250,000
Grants in period, weighted average grant date fair value | $ / shares								$ 1	$ 0.75	$ 1.39
Number of persons | Persons								1	1	1
Options granted, value | $								$ 100,000	$ 75,000	$ 347,500
Financial Advisory Board [Member] | Share-based Payment Arrangement, Option [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares			45,000		3,000	200,000
Grants in period, weighted average grant date fair value | $ / shares			$ 0.61		$ 0.73	$ 0.95
Options granted, value | $			$ 27,450		$ 1,635	$ 141,060
Terms of award			Three-year options		Three-year options	Three-year options
Medical Advisory Board [Member] | Share-based Payment Arrangement, Option [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares													45,000							45,000	3,000
Grants in period, weighted average grant date fair value | $ / shares													$ 1.21							$ 1.10	$ 1.09
Options granted, value | $													$ 44,820							$ 39,731	$ 2,447
Terms of award													Three-year options							Three-year options	Three-year options
2010 Stock Plan [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Stock appreciation rights percentage																								15.00%
Options outstanding number | shares																						341,000
Options granted, value | $																						$ 257,143
Shares issued for services | shares																						1,127,000
Shares issued for services, value | $																						$ 864,551
Stock-based compensation expense | $																						$ 864,551
Weighted-average remaining contractual life options exercisable																						2 years 7 months 24 days
Aggregate intrinsic value for fully vested, exercisable options | $																						$ 0
Aggregate intrinsic value of options exercised | $																						$ 0
Stock options exercised | shares
Options or stock awards available for grant under the 2010 Plan | shares																						11,297,551

Provision for Income Taxes (Det

Provision for Income Taxes (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Deferred Tax Assets:
Net operating loss carryforward	$ 832,590	$ 226,660
Total deferred tax assets	174,840	47,590
Valuation allowance	(174,840)	(47,590)
Deferred tax asset, net of valuation allowance

Provision for Income Taxes (D_2

Provision for Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Tax benefit at federal statutory rate	(21.00%)	(21.00%)

Provision for Income Taxes (D_3

Provision for Income Taxes (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 22, 2017	Dec. 31, 2019	Dec. 31, 2018
Provision for Income Taxes (Textual)
Federal net operating losses		$ 832,590	$ 226,660
Future taxable income			$ 2,870
Net operating loss carry forwards, description		Net operating loss carry forwards (NOL), if not utilized, will expire in 2037 for federal purposes.
U.S. federal corporate income tax rate	21.00%
Income taxes, description		As of the fiscal year 2019, a deduction for issued warrants and stock options and restricted shares awarded from the 2010 Stock Plan for a total of $1,324,035 has not yet been made, for the fiscal year 2018 this total was $72,412.

Commitments and Contingencies (

Commitments and Contingencies (Details)	Dec. 31, 2019USD ($)
Commitments and Contingencies (Textual)
Payment of severance upon termination	$ 100,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Principal Amount	$ 886,900
Warrants Issued	408,333
Debt discount	$ 185,163	$ 77,585
Convertible notes payable [Member]
Principal Amount	236,600
Net Received	$ 209,500
Warrants Issued	72,000
Amortization of Warrants	$ 16,002
Debt discount	$ 31,000
Convertible notes payable [Member] | EMA Financial [Member]
Debtor	EMA Financial
Date of Issuance	Jan. 10, 2020
Maturity Date	Jan. 10, 2021
Principal Amount	$ 125,000
Net Received	$ 109,500
Interest	4.00%
Warrants Issued	50,000
Term	5 years
Exercise Price	$ 2
Amortization of Warrants	$ 5,948
Debt discount	$ 15,500
Convertible notes payable [Member] | Crown Bridge [Member]
Debtor	Crown Bridge
Date of Issuance	Feb. 20, 2020
Maturity Date	Feb. 20, 2021
Principal Amount	$ 55,000
Net Received	$ 48,000
Interest	4.00%
Warrants Issued	22,000
Term	5 years
Exercise Price	$ 2
Amortization of Warrants	$ 10,054
Debt discount	$ 7,000
Convertible notes payable [Member] | PowerUp [Member]
Debtor	PowerUp
Date of Issuance	Feb. 19, 2020
Maturity Date	Feb. 19, 2021
Principal Amount	$ 56,600
Net Received	$ 52,000
Interest	8.00%
Warrants Issued
Term
Exercise Price
Amortization of Warrants
Debt discount	$ 4,600

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	Mar. 12, 2020	Feb. 01, 2020	Jan. 03, 2020	Jan. 02, 2020	Jan. 02, 2019	Feb. 19, 2020	Feb. 18, 2020	Jan. 31, 2020	Nov. 02, 2018	Dec. 31, 2019	Dec. 31, 2018
Subsequent Events (Textual)
Conversion price										$ 0.285	$ 0.51
Issuance of common stock										$ 37,000
Option term										3 years
Face value										$ 886,900
Debt discount										$ 185,163	$ 77,585
Warrants Issued										408,333
2010 Stock Plan [Member]
Subsequent Events (Textual)
Conversion of accrued interest									$ 864,551	$ 864,551
Shares issued for conversion of accrued interest, shares									1,127,000	1,127,000
Share price									$ 0.77	$ 0.77
Medical Advisory Board Member [Member] | 2010 Stock Plan [Member]
Subsequent Events (Textual)
Granted shares					3,000
Option term					3 years
Share price					$ 0.31
Fair value					$ 603
Warrant [Member]
Subsequent Events (Textual)
Granted shares										408,333	208,333
Share price										$ 2
Fair value										$ 236,600
Face value										18,547
Net proceeds										236,600
Debt discount										$ 16,002
Warrants term										5 years
Warrants Issued										72,000
Maturity date										Feb. 25, 2020
Subsequent events [Member]
Subsequent Events (Textual)
Conversion of accrued interest						$ 65
Shares issued for conversion of accrued interest, shares						0.001
Issuance of common stock						$ 15,000
Fair value						236,600
Debt discount						$ 31,000
Warrants Issued						408,333
Subsequent events [Member] | Medical Advisory Board Member [Member] | 2010 Stock Plan [Member]
Subsequent Events (Textual)
Issuance of common stock			$ 100,000				$ 250,000
Granted shares		45,000		250,000				200,000
Option term		3 years
Share price		$ 0.15		$ 0.285				$ 0.14
Fair value		$ 4,401		$ 71,250				$ 28,000
Face value			$ 12,000				$ 21,632
Subsequent events [Member] | Common Stock [Member]
Subsequent Events (Textual)
Issuance of common stock	$ 750,000
Face value	$ 250,500
Warrants Issued	416,666